Patents Assigned to Hadasit Medical Research Services
-
Patent number: 9155595Abstract: The present invention provides a selective coating of an endodontic file, in which the distal end of the file is uncoated or alternatively leaving the outermost part of the blades of the distal end portion uncoated. The distribution of the nanoparticles is thus non uniform along the surface of the file leaving only a part of the file coated. In the present invention, the distal end of the device being subjected to the highest torque is either uncoated at all, or has a coated core and uncoated blades.Type: GrantFiled: June 21, 2011Date of Patent: October 13, 2015Assignees: YEDA RESEARCH AND DEVELOPMENT CO. LTD., HADASIT MEDICAL RESEARCH SERVICES & DEVELOPMENT LTD.Inventors: Reshef Tenne, Meir Redlich, Adi Ram-Adini, Yishay Feldman, Gili Naveh, Joshua Moshonov, Boaz Shay
-
Patent number: 9072737Abstract: The invention relates to tPA mutant devoid of protease activity and uses thereof in compositions and methods for the treatment and prevention of pathologic conditions involving neurological injury or an ischemic disease or condition. More specifically, the invention relates to a Ser481 to Ala mutant of tPA and to compositions and combinations thereof for the treatment of stroke, acute brain injury and neurodegenerative disorders. The invention further provides methods and kits for the treatment of said disorders.Type: GrantFiled: March 16, 2009Date of Patent: July 7, 2015Assignee: HADASIT MEDICAL RESEARCH SERVICES & DEVELOPMENT LTD.Inventors: Abd Higazi, Nuha Hijazi
-
Patent number: 9034814Abstract: The present invention provides novel uses for CXCR4 antagonists, including specifically peptides of the T-140 family, in the treatment of skin burns and other injuries. The invention further provides methods for increasing epithelialization in a subject in need thereof, and for preventing or inhibiting fibrosis and excessive scar formation, using peptide inhibitors of the T-140 family as well as other CXCR4 antagonists.Type: GrantFiled: May 21, 2006Date of Patent: May 19, 2015Assignees: Hadasit Medical Research Services and Development Ltd., Kyoto UniversityInventors: Amnon Peled, Nobutaka Fujii
-
Publication number: 20150125506Abstract: The present invention concerns RPE cells obtainable by directed differentiation from stem cell, particularly, human stem cells. It has been specifically found that culturing stem cells in the presence of one or more member of the TGF? superfamily, such as Activin A) induced directed differentiation into mature and functional RPE cells. This was evidenced by the expression of markers specific to mature RPE cells, including MiTF-A, RPE65 or Bestrophin). In accordance with one particular embodiment, the cells are a priori cultured with nicotinamide (NA) which was found to augment the cells' response to the inductive effect of the one or more member of the TGF? superfamily. The invention also provides methods of performing the directed differentiation, as well as methods for use of the resulting RPE cells.Type: ApplicationFiled: December 29, 2014Publication date: May 7, 2015Applicant: HADASIT MEDICAL RESEARCH SERVICES AND DEVELOPMENT LTD.Inventors: Masha IDELSON, Ruslana ALPER-PINUS, Alex OBOLENSKY, Eyal BANIN, Benjamin Eithan REUBINOFF
-
Patent number: 9023859Abstract: A compound in combination with a pharmaceutically acceptable carrier, the compound having a formula: wherein: R1 is a member of the group consisting of hydrogen, halogen, nitro, benzo, lower alkyl, phenyl, and lower alkoxy; R2 is a member of the group consisting of hydroxy, acetoxy, and lower alkoxy; and R3 is a member of the group consisting of hydrogen and lower alkenoxy-carbonyl; and n is either 1 or 2; and pharmaceutically acceptable salts thereof; for use in treatment of or prevention of skeletal muscle fibrosis and/or for inducing skeletal muscle regeneration.Type: GrantFiled: March 1, 2013Date of Patent: May 5, 2015Assignees: State of Israel, Ministry of Agriculture, Agricultural Research Organization, Hadasit Medical Research Services and Development CompanyInventors: Mark Pines, Arnon Nagler
-
Publication number: 20150118749Abstract: The present invention concerns RPE cells obtainable by directed differentiation from stem cell, particularly, human stem cells. It has been specifically found that culturing stem cells in the presence of one or more member of the TGF? superfamily, such as Activin A) induced directed differentiation into mature and functional RPE cells. This was evidenced by the expression of markers specific to mature RPE cells, including MiTF-A, RPE65 or Bestrophin). In accordance with one particular embodiment, the cells are a priori cultured with nicotinamide (NA) which was found to augment the cells' response to the inductive effect of the one or more member of the TGF? superfamily. The invention also provides methods of performing the directed differentiation, as well as methods for use of the resulting RPE cells.Type: ApplicationFiled: December 29, 2014Publication date: April 30, 2015Applicant: HADASIT MEDICAL RESEARCH SERVICES AND DEVELOPMENT LTD.Inventors: Masha IDELSON, Ruslana ALPER-PINUS, Alex OBOLENSKY, Eyal BANIN, Benjamin Eithan REUBINOFF
-
Patent number: 9005965Abstract: Provided are systems and methods for providing human cell cultures. Further provided are cultures of feeder cells for use in stem cell technology, as well as cultures, culture systems and methods for maintenance and propagating of stem cells in an undifferentiated state as well as for the development of somatic cells cultures from stem cells, the somatic cell cultures being free of extraembryonic cells.Type: GrantFiled: January 13, 2011Date of Patent: April 14, 2015Assignee: Hadasit Medical Research Services & Development LimitedInventors: Etti Ben Shushan, Shelly Tannenbaum, Pavel Itsykson, Eyal Banin, Benjamin Reubinoff
-
Patent number: 8986929Abstract: The present invention identifies genotypes associated with resistance to extrapyramidal symptoms induced by antipsychotic drugs. The present invention further identifies genotypes associated with predisposition to the onset or aggravation of extrapyramidal symptoms induced by antipsychotic drugs and use thereof for assessment of patient populations. Specifically, the present invention relates to particular polymorphisms in the RGS2 gene that are associated with resistance or susceptibility to drug-induced extrapyramidal symptoms.Type: GrantFiled: June 7, 2011Date of Patent: March 24, 2015Assignee: Hadasit Medical Research Services and Development Ltd.Inventors: Bernard Lerer, Lior Greenbaum
-
Patent number: 8980244Abstract: The invention relates to use of the natural cytotoxicity receptor NKp46 for preventing and treating diabetes, including type I diabetes (TID) and type 2 diabetes. In particular, the invention provides compositions comprising a fragment of the extracellular region of NKp46 for preventing the onset and progression of diabetes.Type: GrantFiled: April 15, 2013Date of Patent: March 17, 2015Assignees: Ben-Gurion University of the Negev Research and Development Authority, Hadasit Medical Research Services and Development Ltd., Yissum Research Development Company of the Hebrew University of Jerusalem, Ltd.Inventors: Ofer Mandelboim, Angel Porgador, Yaakov Naparstek, Chamutal Gur
-
Publication number: 20150072979Abstract: The present invention provides compositions and methods for treating, preventing, and inhibiting viral replication, viral infections and viral diseases and disorders, comprising the use of artemisinin derivatives having anti-viral activity.Type: ApplicationFiled: April 17, 2013Publication date: March 12, 2015Applicants: THE HONG KONG UNIVERSITY OF SCIENCE AND TECHNOLOGY, HADASIT MEDICAL RESEARCH SERVICES AND DEVELOPMENTInventors: Richard K. Haynes, Dana G. Wolf
-
Patent number: 8975294Abstract: The present invention relates to methods kits and combined compositions using DFO-metal complexes, specifically, Zinc-desferrioxamine (Zn-DFO), gallium-desferrioxamine (Ga-DFO) complexes and any combinations thereof for preventing, treating, ameliorating or inhibiting an immune-related disorder, specifically, a skin-related inflammatory disorder such as psoriasis, an inflammatory respiratory condition such as asthma, and an autoimmune disease such as diabetes and any immune-related disorder.Type: GrantFiled: August 19, 2010Date of Patent: March 10, 2015Assignees: Hadasit Medical Research Services and Development Ltd., Yissum Research Development Company of the Hebrew University of Jerusalem Ltd.Inventors: Mordechai Chevion, Vladimir Vinokur, Eduard Berenshtein, Ron Eliashar, Baruch Bulvik
-
Patent number: 8962891Abstract: The present invention provides new ceramide analogs indicated as the compounds of formula (II). These novel analogs exhibit a significant anti cancerous effect and are therefore provided as a pharmaceutical composition for treating cell proliferative diseases, neurodegenerative disorders, metabolism-associated conditions, infectious diseases, and immune-related disorders. The invention further provides combined compositions and kits combining the novel ceramide analogs of formula (II) with an additional therapeutic agent.Type: GrantFiled: November 9, 2008Date of Patent: February 24, 2015Assignees: Hadasit Medical Research Services & Development Limited, Yissum Research Development Company of the Hebrew University of Jerusalem, Ltd.Inventors: Arie Dagan, Shimon Slavin, Shimon Gatt, Jeremy Zahavi
-
Patent number: 8956866Abstract: The present invention concerns RPE cells obtainable by directed differentiation from stem cell, particularly, human stem cells. It has been specifically found that culturing stem cells in the presence of one or more member of the TGF? superfamily, such as Activin A) induced directed differentiation into mature and functional RPE cells. This was evidenced by the expression of markers specific to mature RPE cells, including MiTF-A, RPE65 or Bestrophin). In accordance with one particular embodiment, the cells are a priori cultured with nicotinamide (NA) which was found to augment the cells' response to the inductive effect of the one or more member of the TGF? superfamily. The invention also provides methods of performing the directed differentiation, as well as methods for use of the resulting RPE cells.Type: GrantFiled: April 27, 2008Date of Patent: February 17, 2015Assignee: Hadasit Medical Research Services and Development Ltd.Inventors: Masha Idelson, Ruslana Alper-Pinus, Alex Obolensky, Eyal Banin, Benjamin Reubinoff
-
Publication number: 20150037404Abstract: A method for lubricating a joint of a mammal by administering into a cavity of the joint a composition of liposomes that are multilamellar vesicles (MLV) dispersed in a fluid medium, the liposomes having a mean diameter of between about 0.8 ?m to about 10 ?m and including membranes of at least one glycerophospholipid (GPL) having two C12-C16 hydrocarbon chains which are the same or different. These membranes have a phase transition temperature in which solid ordered (SO) to liquid disordered (LD) phase transition occurs, the phase transition temperature being at a temperature of about 20° C. to about 39° C. and being lower than the temperature of the joint.Type: ApplicationFiled: October 22, 2014Publication date: February 5, 2015Applicants: TECHNION RESEARCH AND DEVELOPMENT FOUNDATION LTD., HADASIT MEDICAL RESEARCH SERVICES & DEVELOPMENT LIMITED, YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEMInventors: Yechezkel BARENHOLZ, Dorit NITZAN, Izhak ETSION, Avi SCHROEDER, Grigory HALPERIN, Sarit SIVAN
-
Patent number: 8940537Abstract: The present disclosure provides methods for maintaining and propagating undifferentiated pluripotent stem cells (SC) in suspension. The methods comprise culturing such SC in a non-adherent culture dish under conditions comprising a basic serum free medium and one or more of a basic medium, a serum replacement, an extra cellular matrix component and a factor supporting expansion of said SC. A specific and preferred culture condition comprise supplementing Neurobasal™ medium with KO serum replacement (KOSR). These conditions allowed for large scale and long term propagation of undifferentiated pluripotent SC. The culture system comprising suspended undifferentiated pluripotent SC were found to have many applications including in methods for directed as well as spontaneous differentiation of the SC into somatic cells. Also disclosed herein is a method of deriving SC, preferably human embryonic SC from human embryos via the formation of cell clusters.Type: GrantFiled: January 25, 2012Date of Patent: January 27, 2015Assignee: Hadasit Medical Research Services & Development LimitedInventors: Benjamin Reubinoff, Debora Steiner
-
Patent number: 8895054Abstract: The present invention concerns methods of joint lubrication and/or prevention of cartilage wear making use of liposomes having membranes with at least one phospholipid (PL) of the group consisting of a glycerophospholipid (GPL) having two, being the same or different, C12-C16 hydrocarbon chain and a sphingolipid (SPL) having a C12-C15 hydrocarbon chain, the one or more membranes having a phase transition temperature in which solid ordered (SO) to liquid disordered (LD) phase transition occurs, the phase transition temperature being within a temperature of about 20° C. to about 39° C. for lubrication of joints.Type: GrantFiled: March 26, 2009Date of Patent: November 25, 2014Assignees: Technion Research and Development Foundation Ltd., Hadasit Medical Research Services & Development Limited, Yissum Research Development Company of the Hebrew University of JerusalemInventors: Yechezkel Barenholz, Dorit Nitzan, Izhak Etsion, Avi Schroeder, Grigory Halperin, Sarit Sivan
-
Publication number: 20140341952Abstract: A method for treating a disease comprising administering to a mammal in need thereof an effective dosage of an extract of a plant of the genus Hoodia, wherein the disease is selected from the group consisting of immune-mediated disorders, immune-associated disorders, inflammatory diseases, coronary disease, insulin resistance and liver-related diseases. In a preferred embodiment, the Hoodia is Hoodia parviflora. Also disclosed is a pharmaceutical composition for treating the above diseases comprising an effective dosage of an extract of a plant of the genus Hoodia.Type: ApplicationFiled: December 19, 2013Publication date: November 20, 2014Applicants: HADASIT MEDICAL RESEARCH SERVICES & DEVELOPMENT LTD., BIO-MASS LTD., DESERT LABS AGRICULTURE COOPERATIVE ASSOCIATION LTD.Inventors: Refael Aharon, Yaron Ilan
-
Patent number: 8868194Abstract: The present invention depicts an implantable artificial pacemaker (AAP) comprising oscillatory means providing pulsating signals at a pre-selected frequency, wherein the pacemaker is pacing the aorta. The invention also describes an AAP further comprising; (i) a plurality of sensors disposed internally or externally to the aorta; and (ii) a pacing means in which the AAP stimulates the aortic media, augmenting physiological aortic elastic recoil. An AAP further comprising a processor capable of obtaining information from sensors and triggering an appropriate contraction wave in the aortic media is also introduced. A method of managing aortic rhythm comprising; (i) implanting an AAP comprising oscillatory means; and (ii) pulsating signals at a preselected frequency, so as to pace the aorta and in which the pulsating signals are provided by synchronizing and coordinating activation impulses in a portion of the aorta using electrical impulses is also taught.Type: GrantFiled: March 29, 2007Date of Patent: October 21, 2014Assignee: Hadasit Medical Research Services and Development Ltd.Inventors: Amos Cahan, David Planer
-
Patent number: 8865909Abstract: Novel agents exhibiting anti-biofilm formation activity while being non-cytotoxic are provided, as well as methods of using the same, either per se or conjugated to a polymer, for preventing and/or reducing the formation of microbial biofilms and/or for disrupting microbial biofilms. The novel agents described herein include thiazolidine-2,4-diones (TZDs), pyrrolidine-2,5-diones (PYDs), imidazolidine-2,4-diones or oxazolidine-2,4-diones, substituted by an alkyl having 7-20 carbon atoms in its backbone chain.Type: GrantFiled: November 19, 2009Date of Patent: October 21, 2014Assignees: Yissum Research Development Company of the Hebrew University of Jerusalem Ltd., Hadasit Medical Research Services and Development Ltd.Inventors: Morris Srebnik, Itzhack Polacheck, Doron Steinberg, Adel Jabbour, Edward Sionov
-
Publication number: 20140255403Abstract: This application describes a method of delivering a TNF antagonist molecule, in a biologically active form, to a subject in need thereof, the method comprising, orally or mucosally administering to the subject a therapeutically effective amount of a TNF antagonist molecule. This application further describes a method of treating, preventing or reducing the severity of obesity, the method comprising, administering to the subject a therapeutically effective amount of a TNF antagonist molecule.Type: ApplicationFiled: March 6, 2014Publication date: September 11, 2014Applicant: HADASIT MEDICAL RESEARCH SERVICES & DEVELOPMENT LTD.Inventor: Yaron ILAN